Subcategory
Other indications (e.g. myeloproliferative diseases)
Trial Type
Follow-Up Treatment
Description for experts
MSCs (MC0518) vs. BAT in subjects with steroid-refractory aGvHD after allogeneic HSCT
Description for laymen
MSCs (MC0518) vs. BAT in subjects with steroid-refractory aGvHD after allogeneic HSCT
JSON Data
{
"short_title": "IDUNN / MC-MSC.1",
"data_mode": "910",
"data_mode_number": "000000005",
"official_title": null,
"accrual_state": "running",
"therapeutic_value": "not_applicable",
"therapieansatz_value": "not_applicable",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "rezidiv_haema",
"ctgov_number": null,
"eudract_number": "2019-001462-15",
"general_contact_email": "sal-aml-register@ukdd.de",
"general_contact_phone": "+49 351-45818380",
"hauptpruefer_dd_name": null,
"description_laie_de": "MSCs (MC0518) vs. BAT bei Steroid-refrakt\u00e4rer aGvHD nach allogener HSCT",
"description_laie_en": "MSCs (MC0518) vs. BAT in subjects with steroid-refractory aGvHD after allogeneic HSCT",
"description_expert_de": "MSCs (MC0518) vs. BAT bei Steroid-refrakt\u00e4rer aGvHD nach allogener HSCT",
"description_expert_en": "MSCs (MC0518) vs. BAT in subjects with steroid-refractory aGvHD after allogeneic HSCT",
"rechtsgrundlage_value": null,
"phase_amg_value": null,
"main_cat_id": 4,
"sub_cat_id": 22
}
